Is it possible to improve vascular remodeling by inhibiting the excessive expression of protease-activated receptor 1 (PAR-1) in trophoblast of abnormal placenta?
Introduction
Preeclampsia affects approximately 5% of pregnancies, and poses a health risk to the mother and neonate (Walker, 2000; Roberts and Cooper, 2001 ). However, the pathogenesis of this syndrome is not entirely clear. Recent studies have found that an abnormal placental microenvironment leads trophoblasts to produce excessive antiangiogenesis factors, such as sFlt-1, which may be involved in the pathogenesis of preeclampsia (Page et al., 2000; Maynard et al., 2003) .
In our previous study, we reported that thrombin increased the trophoblast expression of sFlt-1 via protease-activated receptor 1 (PAR-1) (Zhao et al., 2012) . PAR-1, which is a member of the G protein-coupled protease-activated receptors (PARs), is a thrombin high-affinity receptor (Melnikova et al., 2008) . PAR-1 activation was found to mediate several processes in vascular biology, inflammation and tissue remodeling in normal development (Hirota et al., 2005; Antoniak et al., 2016) . In preganancy, PAR-1 is expressed in extravillous trophoblasts and influences human placentation. Abnormally low and overexpression of PAR-1 may be involved in the pathology of complicated placental diseases (O'Brien et al., 2003; GrisaruGranovsky et al., 2009 GrisaruGranovsky et al., , 2015 . As the mediator of the effect of thrombin on coagulation and inflammation, PAR-1 expression is increased in the placentas of women with preeclampsia. It was proposed that the effects of thrombin in preeclampsia were due to increased thrombin generation and higher expression of PAR-1 (Erez et al., 2008) . Our previous study also demonstrated that thrombin and the PAR-1-specific agonist SFLLERN induced trophoblast sFlt-1 mRNA expression and protein secretion, while the thrombin antagonist PPACK blocked this effect, which supported Erez's finding.
We hypothesized that a PAR-1 blocker could be used for regulating trophoblast sFlt-1 expression and ameliorating abnormal placental angiogenesis. Currently, PAR-1-targeting agents or silencing has been assessed for various purposes, such as antiplatelet therapy (Olivier et al., 2013) , prevention of the recurrence of cardiac events (Bhandari and Mehta, 2014; Gurbel et al., 2016) , prevention of ischemic recurrences in patients with atherosclerotic disease (Franchi et al., 2015) , reducing germinal matrix hemorrhage severity in susceptible preterm infants (Lekic et al., 2015) , treatment for pulmonary fibrosis (Lin et al., 2014) , and protecting neurons and astrocytes in stroke therapy (d'Audigier et al., 2015) . In the present study, overexpression plasmids and short hairpin RNA (shRNA) for PAR-1 were transfected into trophoblasts to investigate the effects of inhibiting PAR-1 on the regulation of sFlt-1 production and vascularization at the maternal-fetal interface. We demonstrated that activation of PAR-1 promoted trophoblast sFlt-1 secretion which might be associated with suppression of placental angiogenesis. Inhibiting PAR-1 overexpression could improve placental angiogenesis and vascular remodeling. On the basis of the in vitro experiments, we carried out animal experiments. These showed that PAR-1 shRNA therapy may ameliorate symptoms of preeclampsia and that inhibition of PAR-1 overexpression may serve as an approach for preeclampsia treatment.
Materials and methods

Cell culture
The HTR-8/SVneo cells were a kind gift from the Dr. Charles Graham (Queen's University, Kingston, Ontario, Canada). The cells were cultured in RPMI-1640 medium with 5% fetal bovine serum (Gaithersburg, MD, USA) in 5% CO 2 at 37°C. The cultivated medium was changed every 2 days.
Tissue collection
Villous and decidua tissues were obtained from women who underwent elective abortion of pregnancy in first trimester (between sixth and ninth week of gestation). These samples were collected with the patients' informed consent and this research was conducted after reviewed and approved by Ethical Review Board of Wuhan Union Hospital. Tissue samples were collected and washed in PBS and were later used for placentaldecidua co-culture and immunohistochemistry (IHC). Tissues from 12 pregnant women were collected for co-culture and IHC staining.
In vitro transfection
HTR-8/SVneo cells were transfected with a mixture containing plasmids with the PAR-1 shRNA (shPAR-1) or PAR-1 overexpression plasmids (PAR-1) as well as Neofect transfection reagent for 48 h (Genechem Co., Ltd., Shanghai, China). Fluorescence microscopy was then used to observe the transfection efficiency. ELISA analyses were conducted to detect mRNA and protein secretion.
Q-PCR analysis
Total RNA was extracted using an RNA isolation reagent (TaKaRa, Dalian, China) following the manufacturer's instructions. Total RNA (1 μg) was reverse transcribed into cDNA in a 20 μl volume with PrimeScript RT Master Mix (TaKaRa, Dalian, China). Cell mRNA expression was detected by PCR and data analysis was performed with a Step One Plus system (Applied Biosystems) according to the manufacturer's instructions. cDNA (1 μl in a 10 μl volume) was amplified using oligo-nucleotide primers. Each sample was normalized to the house-keeping gene GAPDH, and the results were estimated with a melting curve analysis. The primer sequences were as follows:
PAR-1 sense primer, 5′-GGCTGACACTCTTTGTCCCA-3; PAR-1 anti-sense primer, 5′-CCAAACTGCCAATCACTGCC-3; GAPDH sense primer, 5′-GCACCGTCAAGGCTGAGAAC-3′; GAPDH anti-sense primer, 5′-TGGTGAAGACGCCAGTGGA-3′.
Western blot analysis
Proteins were extracted from cells and the placenta. Cell lysates were electrophoresed in SDS-PAGE and transferred to PVDF membranes. The membranes were incubated by specific antibodies at 4°C overnight. Polyclonal Par-1 antibody from ABcam (Cambridge, England) and monoclonal Par-1 antibody from Affinity Biosciences (OH, USA) were used, then the membranes washed three times with TBST and incubated again with secondary antibodies for 1 h. The band was exposed by the ECL system and analyzed with Image J software.
Enzyme linked immunosorbent assay
Conditioned culture media were centrifuged and stored at −80°C until assay. sFlt-1, PLGF, VEGF were measured in cultured supernatants collected from cell transfection and controls. sFlt-1, PLGF and VEGF proteins were detected with ELISA kits following the instructions (R&D system, Minneapolis, MN, USA). Quantification of the protein level was measured with a microplate reader at a wavelength of 450 nm.
Tube formation assay
Tube formation assays were performed using the method previously described (Zhao et al., 2014) . HUVECs were isolated by collagenase digestion and cultured with DMEM/F12 medium containing 10% FBS for 24 h. Matrigel Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA) was added to 24-well plates for a total volume of 200 μl in each well. The plates were stored at 37°C for 1 h to enable formation of a gel layer. After gel formation, 500 μl of HUVECs (5 × 10 4 cells) were plated in medium containing 10% FBS with conditioned. The conditioned media was collected from cultured HTR-8/SVneo cells transfected with shPAR-1 or PAR-1 overexpression plasmids. After incubation for 6 h, the cells were observed with an inverted phase-contrast microscope (Olympus, Shinjuku, Tokyo, Japan) and photographed. The mean number of branch points was calculated under the 200× eyepiece in five fields of view.
Placenta and decidua co-culture system
The establishment of a platelet and the decidua co-culture (PDC) system were conducted as previously reported (Luo et al., 2015) . First 100 μl of Matrigel was added to the upper area of a 12-well co-culture chamber and incubated at 37°C for 1 h. Human early pregnancy decidua and villous tissues were collected, and the decidua was cut into 2 × 2 cm 2 patches and placed on coagulated Matrigel glue. Then the villous tissue was scattered on the decidua tissue and co-cultured with different condition media from cells containing 1 μg PAR-1 overexpression or inhibition plasmids in 2% O 2 at 37°C for 6 days. After incubation, the decidua was fixed with paraformaldehyde, and immunohistochemical staining was performed.
Immunohistochemistry analysis
For the immunohistochemistry assay, 5 μm paraffin sections were used. Rehydrated paraffin was heated in citrate buffer (pH 6.0) for antigen retrieval for 15 min. Then, 3% H 2 O 2 was used to quench endogenous peroxidase activity for 20 min. The sections were incubated for 1 h at room temperature with a primary antibody (CD34 1:400, a-SMA 1:400, CK-7 1:400 antibodies, Boster, Wuhan, China). The slides were incubated for another 30 min with an HRP-conjugated goat anti-rabbit IgG (1:1000; Santa Cruz). The slides were then developed with diaminobenzidine for 5 min and hematoxylin for 2 min. Vascular endothelial, smooth muscle cell and trophoblasts were, respectively, stained with CD34, a-SMA and CK-7 antibodies. The vascular remodeling was observed under a microscope.
Development of PE-like rat model
Rats were maintained under strict adherence to Huazhong University of Science and Technology institutional guidelines. Specific pathogen-free 8-week-old Wistar rats (200-250 g) were purchased from the laboratory animal centre of the Hubei centre for disease control (CDC) and were raised at the animal laboratory of Tongji Medical College after obtaining approval from the animal ethics committee. The animals were housed under SPF conditions and were allowed free access to sterilized drinking water and food with a stable temperature and a 12-h light/dark schedule. Each female rat was mated with a male overnight. The female rats were examined the next morning using vaginal smear tests. Gestated day (DG) 0 of pregnancy was defined when spermatozoa were detected in a vaginal smear. On DG 10 of pregnancy, the rats (n = 18) were randomly divided into three groups (6 rats in each group). The blank control group received with 20 μl saline injection, and the preeclampsia group received daily L-NAME (50 mg/kg) through an intraperitoneal injection from DG 11 to DG 19. In the treatment group, the established rats were transfected with PAR-1 shRNA (20 μl transfection compounds contained 10 μg shRNA) by placental injection on DG 16 of gestation. All experimental procedures were performed according to the rules for the use and care of animals. The rats were euthanized at gestated Day 20 of pregnancy with a laparotomy, and their placentas were collected for IHC staining. The number and weight of the placentas and pups were recorded. Systolic blood pressure (SBP) was measured in calm, warmed and restrained on DG 15 and DG 19 using a non-invasive sphygmomanometer with a pneumatic tail cuff device (SoftronBP-98A, Tokyo, Japan), as previously described . Urine samples were analyzed for proteinuria using pyrogallol phenol red kit (DiaSys Diagnostic, Germany) in automatic biochemical analyzer (Hitachi 7600-020, Japan).
In vivo transfection
In vivo transfection was performed using Attractene Transfection Reagent (Qiagen, Germany) according to previous report (Xie et al., 2011) . Transfection compounds were prepared by following the manufacturer's instructions at the optimal concentration (20 μl transfection compounds contained 10 μg shRNA). In all rats, the compounds were locally injected into the placenta on DG 16 via laparotomy. Then, the animals were euthanized on DG 20 for the collection of placentas and foetuses. The in vivo transient transfection efficiency of shRNA was determined by observing the expression of GFP in frozen sections of placenta under fluorescence microscopy. The inhibition efficiency of PAR-1 in rat placenta was detected using Western blotting.
Plasma preparation
On Day 20 of pregnancy, the rats were anesthetized with 10% chloral hydrate, and their femoral venous blood was collected in precooled heparinized vacutainers and centrifuged at 2400 g for 10 min at 4°C. The plasma was removed and stored in 250 μl aliquots at −80°C.
Immunohistochemical staining analysis
The placentas were fixed in 4% paraformaldehyde for 12 h, embedded in paraffin and sectioned for haematoxylin and eosin (H&E) staining to evaluate morphological changes. An anti-CD34 (Abcam, 1:200) antibody was used for IHC staining to indicate the microvessels in the placentas. In the IHC staining analysis, microvessel density (MVD) was analyzed by counting the average number of vessels formed by CD34+ cells in 10 random high-power fields of each section. The microvessel distribution in the placenta of each group of rats was also observed.
Statistical analysis
The data are shown as the mean ± SEM. The results were sorted with SPSS 20.0 software and GraphPad Prism 5 and analyzed statistically using a t-test and ANOVA. P < 0.05 indicated statistical significance. QT-PCR showed that the relative level of PAR-1 mRNA expression was significantly inhibited by shPAR-1 compared with that of the vehicle (P < 0.001). (C) Western blotting showed that PAR-1 protein in shPAR-1 group was down-regulated compared with that of the vehicle. ß-actin was used as an internal control (P < 0.01). (D) HTR-8/ SVneo cells transfected with the PAR-1 overexpression plasmid under bright-field microscopy illumination, and fluorescent light in the same field showed stable and high expression of GFP. (E) QT-PCR showed that the relative level of PAR-1 expression was significantly increased compared with that of the vehicle (P < 0.05). (F) Western blotting showed that PAR-1 protein in overexpression group was significantly higher than that of the vehicle (P < 0.01).
Values are shown as the mean ± SEM of five independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
Efficiency of transfection and silencing PAR-1 in vitro HTR-8/SVneo cells were transfected with 1 μg of PAR-1 shRNA or overexpression plasmids for 48 h. All cells presented stable fluorescence signal (Fig. 1A and D) . PAR-1 mRNA and protein expression were significantly inhibited by shRNA (Fig. 1B and C) , while the overexpression group showed significantly increased PAR-1 levels compared with the control (Fig. 1E and F) .
Inhibition or promotion of PAR-1 changed sFlt-1, PLGF and VEGF expression in HTR-8/SVneo cells After HTR-8/SVneo cells were transfected with PAR-1 inhibition and overexpression plasmids, sFlt-1, PlGF and VEGF secretion protein levels in the supernatant were detected by ELISA assay. The overexpression plasmid significantly increased sFlt-1 secretion, whereas inhibition suppressed sFlt-1 expression. Inhibition treatment promoted VEGF protein expression. PlGF expression was not changed significantly after being treated with inhibition or overexpression plasmid treatment ( Fig. 2A) . Fig. 2C ; vs. control, P < 0.05). PAR-1 overexpression plasmid transfected HTR-8/SVneo media inhibited HUVEC tube formation ( Fig. 2C ; P < 0.001 vs. control). Values are shown as the mean ± SEM of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001). The control group showed the normal remodeling of arteries (red arrows), while endothelial layers (C1, CD34 positive) could be identified, but were not incomplete, the outline of vascular muscle (C2, α-SMA positive) layers was not clear and there were CK7+ trophoblasts present (C3). (D1-3) In the PAR-1 overexpression plasmid transfected group, endothelial disruption at superficial areas was observed (D1), along with intact arteries or early remodeling with complete vascular muscle layer (D2) and trophoblast invasion was rare (D3) (yellow arrows). (E1-3) Inhibition of PAR-1 resulted in the remodeling process, as remodeled arteries could be found in deeper areas (blue arrows), a faint trace of the endothelial layer existed (E1), along with isolated vascular muscle layers (E2) and more invasion of trophoblasts (E3). Samples were collected from 12 pregnant women total.
Inhibiting PAR-1 improved tube formation was accompanied by decreased expression of sFlt-1 HTR-8/SVneo cells culture supernatants were used to cultivate HUVECs. The sFlt-1 level of the conditioned media was lower in inhibition group, and higher in overexpression group compared to the control. Co-culture with conditioned media from shPAR-1 transfected H8 cells resulted in an increase in the total number of branching points, while overexpression plasmid transfected HTR-8/SVneo media inhibited HUVEC tube formation ( Fig. 2B and C) .
Effects of PAR-1 on villus and decidua co-culture system
A villus and decidua co-culture system was conducted to further explore the effect of PAR-1 on placental artery remodeling. Unremodelled arteries were characterized by multiple layers of vascular smooth muscle cells (VSMCs, α-SMA positive), intact endothelial cell (EC, CD34 antibody positive) layer and absence of trophoblast invasion (CK7 antibody negative) (Fig. 3A) . Active remodeling was characterized by trophoblast invasion, endothelial desquamation and disruption of VSMCs (Fig. 3B) . Figure 3C shows normal artery remodeling of trophoblast. Figure 3E shows that after co-culture for 6 days, shPAR-1 treatment groups hadmore advanced remodeling and deeper invasion than the control. Figure 3D shows that artery remodeling was inhibited in the PAR-1 high expression group. Compared to control, intact arteries and early remodeling vessels could be seen, and invaded trophoblast were seldom. In contrast, remodeling in decidua was enhanced in the inhibition group, which had changes in morphology that showed that endothelial and VSMA cells were disintegrated and the vascular lumen increased along with a thinning of the blood vessel walls.
Inhibiting PAR-1 ameliorated symptoms of preeclampsia rats
We next explored the potential therapeutic effects of PAR-1 shRNA in an L-NAME-induced preeclampsia model (Fig. 4A) . High transfection efficiency of GFP was observed in rat placenta (Fig. 4B) . Western blotting exhibited that PAR-1 expression was increased in the animal model group, and substantially decreased by specific shRNA (Fig. 4B) .
The results showed that the L-NAME-induced preeclampsia model was successfully developed and the rats were characterized by increased systolic blood pressure (SBP) and proteinuria. shPAR-1 administration ameliorated the symptoms of preeclampsia in rats, as SBP and proteinuria was reduced dramatically (Fig. 5A and E) . Compared with the significantly increasing blood pressure in the preeclamspia group, after giving shRNA injection, the blood pressure was controlled (Fig. 5B-D) . To investigate the effects of treatment on . Systolic blood pressure (SBP) was higher in preeclampsia rats (n = 6) compared with controls (n = 6) (140.83 ± 1.08 vs. 106.33 ± 2.08 mmHg, P < 0.001),and decreased in treatment group (n = 5) compared with the preclampsia group (123.60 ± 1.47 mmHg, P < 0.001). SBP on D19 were compared with that on D15 in the different groups. (B) In the control group, SBP was not pregnancy outcomes in rats, fetal and placental weights and fetus numbers were compared. Treatment with shPAR-1 benefitedfeto-placental development as shown by increased placental weights (Fig. 5F ) and fetal weights (Fig. 5G) , while the fetal numbers were not different in each group (Fig. 5H ).
Therapeutic effect of shPAR-1 depended on suppression of sFlt-1 expression
Inhibiting PAR-1 overexpression in PE rats improved the balance of pro-and anti-angiogenesis factors expression (Fig. 6A) . The histopathological changes of the placental microvessels showed that in the preeclampsia group, the number of positive blood vessels was reduced, while in treatment group, placental microvasculature was improved ( Fig. 6B and C) . These findings suggest that shPAR-1 may ameliorate symptoms of preeclampsia in rats mainly via the suppression of the sFlt-1-induced anti-angiogenesis effect.
Discussion
Successful placentation depends on the completion of a series of processes to establish the placental vascularization in which the most important process is placenta angiogenesis and spiral artery remodeling. Abnormal placental vascularization may lead to inefficient placental perfusion, which results in the development of preeclampsia. Various factors are involved in abnormal placental angiogenesis and vascular remodeling. A high coagulation state, local placental ischemia, hemorrhage and fibrin deposits are commonly observed in preeclampsia (Zhao et al., 2012) . Erez et al. (2008) proposed that preeclampsia is associated with increased thrombin generation and higher expression of PAR-1. PAR-1 is a protease-activated G protein-coupled receptor cleaved by thrombin. PAR-1 activation mediates the effects of thrombin on platelet activation (Judge et al., 2015) , proinflammatory cytokine secretion (Li and He, 2006) , chemotactic gene expression and leukocyte recruitment (d'Audigier et al., 2015) . PARs have been reported to act as thrombin receptors in pregnancy. Grisaru-Granovsky and colleagues found that PAR-1 gene polymorphisms are associated with adverse pregnancy outcomes (Grisaru-Granovsky et al., 2007 . O'Loughlin's study showed that PAR-1 is potentially a regulator of feto-placental blood flow in normal pregnancy and linked with the vascular destruction associated with preeclampsia (O'Loughlin et al., 2005) . These studies showed that PAR-1 might be an important regulatory step in the pathology of placental vascular development.
In the first trimester, various placental cells, including trophoblasts, decidua cells, endothelial cells and others, participate in the balance of pro-and anti-angiogenesis factors coordinating the promotion of placental vascularization. sFlt-1 is a splice variant of the VEGF receptor that is prominently produced by placental trophoblasts. It antagonizes the activity of VEGF and PlGF, leading to endothelial dysfunction (Palmer et al., 2016) .
In a study of the relationship between sFlt-1 and PAR-1, Lockwood et al. (2007) showed that first trimester decidua cells express sFlt-1 and that the expression is enhanced by thrombin. Endothelial cells also secrete sFlt-1, and this secretion is induced by the activation of PAR-2, a receptor activated by blood coagulation serine proteinases (Al-Ani et al., 2010) . Our previous study showed that thrombin and the PAR-1-specific agonist SFLLRN increases trophoblast sFlt-1 mRNA expression and protein production (Zhao et al., 2012) . Huang et al. (2015) subsequently reported that NADPH dependent oxidative stress might be one of the mechanisms of thrombin-mediated sFlt-1 secretion. We furthermore found that hypoxia leads to trophoblast increased sFlt-1 release, and the free radical scavenger edaravone can inhibit hypoxia-induced oxidative stress formation and sFlt-1 expression in trophoblasts (Zhao et al., 2014) . Utero-placental hemorrhage, fibrin deposition, and infarction are commonly observed in established preeclampsia (Zhao et al., 2012) . Infarction may lead to localized hypoxia and elevated inflammatory factors, such as TNF-α expression. The elevated TNF-α in the placenta may promote PAI-1 and tissue factor production (Estelles et al., 1998) . Increased placental tissue factor induces a resultant thrombin activation of PAR-1 and leading to excess sFlt-1 secretion (Gardiner and Vatish, 2017) . Thus, thrombotic alterations in placenta, hypoxia and inflammatory are the inseparable factors which upregulates PAR-1 activation which contributes to the pathogenesis of preeclampsia. Therefore, controlling the overactivation of PAR-1-mediated sFlt-1 pathway may be a potential therapeutic strategy for preeclampsia.
We hypothesized that inhibition of PAR-1 overexpression may ameliorate placental vascular dysplasia. We confirmed that PAR-1 inhibition contributes to decreased anti-angiogenesis factor sFlt-1 secretion by showing that PAR-1-specific shRNA exerted an inhibitory effect on trophoblasts even under conditions of thrombin simulation. We also detected two other important angiogenesis factors in pregnancy, free PlGF and VEGF secretion. Activating PAR-1-induced PlGF and VEGF expression to a certain extent, which was consistent with the results for human VSMCs (Arisato et al., 2003) , epithelial cells (Bian et al., 2007) and cancer cells (Liu et al., 2006) . In our previous study, we found that activation of PAR-1 by thrombin increases mRNA expression of VEGF but does not change VEGF secretion. It was possible that the increase in sFlt-1 overwhelms VEGF levels and consequently diminishes the biological effects of VEGF in trophoblasts. The level of PlGF, both mRNA and protein levels, is not changed by thrombin (Zhao et al., 2012) . In the present study, activating of PAR-1 had little effect on trophoblast expression of VEGF and PLGF. However, treatment with shRNA apparently promoted VEGF secretion. This evidence suggests that PAR-1 may be an important link for maintaining the balance of pro-and anti-angiogenesis factors during pregnancy. Excessive PAR-1 expression or activation may interfere with normal placental vascularization. Controlling overexpression of changed during pregnancy (D19: 106.33 ± 2.08 vs. D15: 102.67 ± 1.36 mm Hg, P > 0.05). (C) In the preeclampsia group, SBP was increased significantly (D19: 140.83 ± 2.16 vs. D15: 119.40 ± 2.08 mmHg, P < 0.001). (D) In the treatment group, SPB was similar between D19 and D15 (D19: 123.60 ± 1.47 vs. D15: 122.00 ± 0.89 mmHg, P > 0.05). (E) Proteinuria was detected on DG 19, and the proteinuria level was decreased in the treatment group compared with the preeclampsia group (2.10 ± 0.16 vs. 4.48 ± 0.36 vs. 2.64 ± 0.25 μg/μl, control vs. PE vs. treatment group, P < 0.001). (F-H) Compared with the rats with preeclampsia, placental weights and fetal weights were improved in treatment group. Fetal numbers were not different between groups. All data are representative of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
PAR-1 may be an alternative method to return the abnormal expression of angiogenic factors to normal.
The tube formation assay was used to study the effects of inhibiting PAR-1 expression in placental angiogenesis. We believe that PAR-1-regulated sFlt-1 production might be one of the most important factors affecting angiogenesis. Our previous study confirmed that hypoxia induces sFlt-1 expression in trophoblasts and suppresses HUVEC tube formation (Zhao et al., 2014) . Thus, hypoxia, high local thrombin levels and overexpression of PAR-1 in the placenta may enhance sFlt-1 expression and contribute to dysfunctional placenta angiogenesis. Controlling any factor which causes excessive expression of sFlt-1 may ameliorate the abnormal vascularization of the maternal-fetal interface and prevent preeclampsia.
Co-culture of decidua and villous further confirmed that inhibiting PAR-1 activation benefited placental vascular remodeling. In a normal pregnancy, trophoblasts invade into decidua arterioles moderately, substitute vascular endothelial cells and accomplish placental vascular remodeling to meet the demand for blood and oxygen supplies. In the PAR-1 overexpression group, vascular endothelial cells and smooth muscle cells become incompletely detached, and are inefficiently invaded and replaced by trophoblasts, resulting in dysfunction of vascular remodeling. Nevertheless, down-regulating PAR-1 expression promotes endothelial cell and smooth muscle cell separation and trophoblast invasion and substitution, facilitating the completion of the vascular remodeling which maintains successful pregnancy.
In this study, the administration of PAR-1 shRNA into the placenta of preeclampsia rats significantly ameliorated the symptoms of preeclampsia, by decreasing both blood pressure and proteinuria, thus protecting the feto-placental development. The balance of antiangiogenesis factors secretion was therefore recovered in the treatment group. Accordingly, immunohistochemical examination showed that microvessel density increased which suggested that placental perfusion may be improved. These studies showed the potential efficacy of PAR-1 inhibition for controlling abnormal placental vascularization and symptoms in preeclampsia. However, since the expression of PAR-1 was not determined in the fetal tissues, we cannot know whether the altered fetal size is actually dependent on the change in placental vessels,warranting further study. Figure 6 The effect of silencing PAR-1 on sFlt-1, PlGF and VEGF expression and microvessels density in placenta. The serum levels of sFlt-1, PlGF and VEGF were measured by ELISA. In the preeclampsia group, (A1) the sFlt-1 protein level was significantly higher than that of the control group (1.44 ± 0.33 vs. 2.92 ± 0.85 ng/ml, P < 0.001), while VEGF (A2, 176.87 ± 0.68 vs. 129.77 ± 1.04 ng/ml, P < 0.001) and PlGF (A3, 146.04 ± 8.47 vs. 87.23 ± 3.40 ng/ml, P < 0.01) were signicantly lower. In contrast, in the treatment group, (A1) sFlt-1 production was reduced (0.92 ± 0.06 ng/ml vs. the preeclampsia group, P < 0.001), while VEGF (A2, 170.38 ± 3.64 ng/ml, vs. preeclampsia group, P < 0.001) and PlGF (A3, 112.83 ± 5.50 ng/ml, vs. preeclampsia, P < 0.05) secretions were recovered compared with that of the preeclampsia group. Values are shown as the mean ± SEM of four independent experiments. (B) Treatment of the placenta with shPAR-1 improved placental angiogenesis. H&E staining shows the histopathological changes of the placenta microvasculature. In the preeclampsia group, CD34 antibody staining showed the number of positive blood vessels was reduced. In the treatment group, the number of blood vessels and the lumina of the blood vessels were improved. (C) The vessel density was significantly decreased in the preeclampsia group, but in shPAR-1 transfection group, the microvasculature was improved (P < 0.001). Values are shown as the mean ± SEM of four independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
Abnormal placental angiogenesis is one of the possible pathologies of preeclampsia. Anti-angiogenesis factor sFlt-1 appears to be the common key pathway that induces abnormal angiogenesis and vascular remodeling. This study demonstrated that inhibiting PAR-1 overexpression reduces sFlt-1 production and improves vascularization in the maternal-fetal interface. Collectively, the findings indicates that a PAR-1-mediated pathway might serve as a potential therapeutic target for preeclampsia.
